Covered recipient · General Payments record
NABIL H TAUK
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2018–2024
$4,038.96
- Reported across 85 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $871.09 | 19 |
| Education | $9.61 | 4 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $366.65 | 11 |
| Retrophin, Inc. | $134.61 | 5 |
| Relypsa, Inc. | $124.89 | 1 |
| Novo Nordisk AS | $112.22 | 1 |
| Acerta Pharma LLC | $84.09 | 2 |
| ABBVIE INC. | $24.26 | 1 |
| Otsuka America Pharmaceutical, Inc. | $19.44 | 1 |
| ANI Pharmaceuticals, Inc. | $14.54 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (23)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.26 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106204538 | CMS |
| Amgen Inc. | $7.84 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171256 | CMS |
| Amgen Inc. | $148.62 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117698142 | CMS |
| Amgen Inc. | $16.47 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171262 | CMS |
| Amgen Inc. | $31.35 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171268 | CMS |
| Amgen Inc. | $17.76 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171282 | CMS |
| Amgen Inc. | $17.73 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171276 | CMS |
| Amgen Inc. | $24.69 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171288 | CMS |
| Amgen Inc. | $22.82 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171296 | CMS |
| Amgen Inc. | $24.09 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171302 | CMS |
| Amgen Inc. | $29.53 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171308 | CMS |
| Amgen Inc. | $25.75 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116171316 | CMS |
| ANI Pharmaceuticals, Inc. | $14.54 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091173126 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.46 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104681263 | CMS |
| AstraZeneca Pharmaceuticals LP | $62.63 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104217373 | CMS |
| Novo Nordisk Inc | $112.22 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097651040 | CMS |
| Otsuka America Pharmaceutical, Inc. | $19.44 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118992234 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 04/25/2024 | Education | Undisputed | 01/23/2026 | 1149948577 | CMS |
| Travere Therapeutics, Inc. | $0.37 | 06/20/2024 | Education | Undisputed | 01/23/2026 | 1149948573 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 06/20/2024 | Education | Undisputed | 01/23/2026 | 1149948581 | CMS |
| Travere Therapeutics, Inc. | $125.00 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149948589 | CMS |
| Travere Therapeutics, Inc. | $3.08 | 07/25/2024 | Education | Undisputed | 01/23/2026 | 1149948584 | CMS |
| Vifor Pharma, Inc. | $124.89 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124064828 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.